100,358 Shares in GSK PLC Sponsored ADR $GSK Acquired by Leuthold Group LLC

Leuthold Group LLC bought a new position in GSK PLC Sponsored ADR (NYSE:GSK) during the fourth quarter, Holdings Channel.com reports. The fund bought 100,358 shares of the pharmaceutical company’s stock, valued at approximately $4,922,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Valeo Financial Advisors LLC raised its holdings in shares of GSK by 6.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 14,932 shares of the pharmaceutical company’s stock worth $732,000 after purchasing an additional 854 shares in the last quarter. Coston McIsaac & Partners raised its holdings in shares of GSK by 17.3% in the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after purchasing an additional 206 shares in the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in shares of GSK in the 4th quarter worth approximately $6,385,000. Horizon Investments LLC raised its holdings in shares of GSK by 5.7% in the 4th quarter. Horizon Investments LLC now owns 20,061 shares of the pharmaceutical company’s stock worth $984,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Verity Asset Management Inc. raised its holdings in shares of GSK by 12.5% in the 4th quarter. Verity Asset Management Inc. now owns 23,144 shares of the pharmaceutical company’s stock worth $1,135,000 after purchasing an additional 2,567 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GSK has been the topic of a number of recent analyst reports. Barclays restated an “underweight” rating on shares of GSK in a report on Friday, February 20th. TD Cowen restated a “hold” rating on shares of GSK in a report on Monday, February 9th. Wall Street Zen lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 7th. Weiss Ratings upgraded shares of GSK from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday, May 1st. Finally, Citigroup restated a “neutral” rating on shares of GSK in a report on Monday, February 9th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $53.00.

GSK Stock Down 2.5%

GSK stock opened at $49.66 on Friday. GSK PLC Sponsored ADR has a 52-week low of $35.45 and a 52-week high of $61.69. The company’s 50 day simple moving average is $54.33 and its 200-day simple moving average is $52.07. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. The firm has a market capitalization of $100.78 billion, a P/E ratio of 12.91, a P/E/G ratio of 2.53 and a beta of 0.38.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be given a dividend of $0.44 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.76 dividend on an annualized basis and a yield of 3.5%. GSK’s payout ratio is presently 48.83%.

GSK Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.